In vitro Activity of Enrofloxacin, Marbofloxacin and Ciprofloxacin Against Clinical Strains of Pseudomonas spp Isolated from Small Animals on Portugal
WSAVA 2002 Congress
*Constança Pomba-Féria, Marta Costa, Manuela Caniça, José Duarte Correia
*CIISA, Faculty of Veterinary Medicine, Rua Prof. Cid dos Santos
Lisbon, PT
cferia@fmv.utl.pt

OBJECTIVES

The aim of this study was to evaluate the in vitro activity of veterinary fluoroquinolones Enrofloxacin and Marbofloxacin and human fluoroquinolone Ciprofloxacin in clinical strains of Pseudomonas spp isolated from small animal samples, at the Laboratório de Análises Clínicas Prof. Dr. Braço Forte, Faculty of Veterinary Medicine.

MATERIALS

36 pathogenic strains of Pseudomonas spp of animal origin were isolated, 75% of them from otitis externa, 19.4% from urinary tract infection, and 5.6% from other infections. Of these, 58.3% were identified as Pseudomonas aeruginosa. Pseudomonas aeruginosa ATCC 27853 strain was used as control. Minimal Inhibitory Concentrations (MIC) were determined by broth microdilution according to NCCLS guidelines. For the veterinary fluoroquinolones, the NCCLS(M31-T,1997) veterinary criteria were applied, for Ciprofloxacin the NCCLS (2000) human breakpoints were used.

RESULTS

Enrofloxacin had a MIC50 of 1 µg/ml and a MIC90 of 32 µg/ml, MIC values ranged from 0.125 to 64 µg/ ml. Marbofloxacin MIC50 and MIC90 were 0.5 and 16 µg/ml, respectively, with values going from 0.0125 to 32 µg/ml. The MIC50 and MIC90 of Ciprofloxacin are lower than the ones for the veterinary fluoroquinolones, respectively 0.125 and 8 µg/ml, raging from 0.0625 to 16 µg/ml. Nevertheless Ciprofloxacin MIC90 is already beyond the defined breakpoint for resistance.

CONCLUSION

In this study the MIC50 found for Enrofloxacin (1 µg/ml) was above the susceptible NCCLS criteria which probably reflects its indiscriminate use. We also found low level of resistance in veterinary clinical strains to Enrofloxacin's metabolite Ciprofloxacin, which is of concern: Ciprofloxacin had greater efficacy in vitro against clinical veterinary Pseudomonas isolates than the veterinary quinolones, in spite of the detection of four resistant strains (11,4%). This work reports significant resistance of Pseudomonas veterinary isolates and supports the need for a rational antibiotic prescribing policy, in order to prevent the selection of resistant strains.

Speaker Information
(click the speaker's name to view other papers and abstracts submitted by this speaker)

Constança Pomba-Féria
CIISA, Faculty of Veterinary Medicine
Rua Prof. Cid dos Santos
Lisbon, Lisbon 1300-477 PT

José Duarte Correia
CIISA, Faculty of Veterinary Medicine

Manuela Caniça
Antibiotic Resistance Unit, NIH Dr. Ricardo Jorge

Marta Costa
CIISA, Faculty of Veterinary Medicine and Laboratórios Atral-Cipan


MAIN : : Enrofloxacin, Marbofloxacin and Ciprofloxacin
Powered By VIN

Friendly Reminder to Our Colleagues: Use of VIN content is limited to personal reference by VIN members. No portion of any VIN content may be copied or distributed without the expressed written permission of VIN.

Clinicians are reminded that you are ultimately responsible for the care of your patients. Any content that concerns treatment of your cases should be deemed recommendations by colleagues for you to consider in your case management decisions. Dosages should be confirmed prior to dispensing medications unfamiliar to you. To better understand the origins and logic behind these policies, and to discuss them with your colleagues, click here.

Images posted by VIN community members and displayed via VIN should not be considered of diagnostic quality and the ultimate interpretation of the images lies with the attending clinician. Suggestions, discussions and interpretation related to posted images are only that -- suggestions and recommendations which may be based upon less than diagnostic quality information.

CONTACT US

777 W. Covell Blvd., Davis, CA 95616

vingram@vin.com

PHONE

  • Toll Free: 800-700-4636
  • From UK: 01-45-222-6154
  • From anywhere: (1)-530-756-4881
  • From Australia: 02-6145-2357
SAID=27